Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis

Pravesh Kumar Bundhun and Feng Huang

Abstract

Background: Due to limitations associated with clopidogrel following percutaneous coronary intervention (PCI), other newer oral anti-platelet agents are being studied. We aimed to systematically carry out a direct comparison of outcomes observed with prasugrel versus clopidogrel following PCI.

Methods: Common online searched databases (The Cochrane library, EMBASE, MEDLINE and Google scholar) were used to retrieve relevant publications. Primary endpoints were the adverse cardiovascular outcomes. Secondary outcomes were the bleeding events. This analysis was carried out by RevMan 5.3, whereby odds ratios (OR) and 95% confidence intervals (CI) were considered as the statistical parameters.

Results: Eight studies with a total number of 18,122 participants were included in this direct analysis. Prasugrel was associated with significantly lower adverse cardiovascular outcomes in comparison to clopidogrel following PCI. All-cause mortality, myocardial infarction, stroke, stent thrombosis and major adverse cardiac events were all significantly lower with prasugrel (OR: 0.47, 95% CI: 0.35–0.63; P = 0.0001), (OR: 0.68, 95% CI: 0.57–0.80; P = 0.00001), (OR: 0.60, 95% CI: 0.38–0.96; P = 0.03), (OR: 0.46, 95% CI: 0.30–0.72; P = 0.0006) and (OR: 0.61, 95% CI: 0.53–0.70; P = 0.00001) respectively.

When the bleeding outcomes were analyzed, Thrombolysis in Myocardial Infarction (TIMI) defined major and minor bleeding were not significantly different (OR: 0.91, 95% CI: 0.66–1.27; P = 0.59) and (OR: 1.16, 95% CI: 0.85–1.59; P = 0.35) respectively. However, the combined ‘all bleeding events’ was significantly higher with prasugrel (OR: 1.32, 95% CI: 1.03–1.70; P = 0.03), but when patients with STEMI and those undergoing elective PCI were separately analyzed, no significant difference in overall bleeding was observed.

Conclusion: Adverse cardiovascular outcomes were significantly lower with the use of prasugrel in comparison to clopidogrel following PCI. In addition, TIMI defined major and minor bleeding were not significantly different showing prasugrel to be well-tolerated following PCI especially in patients with acute coronary syndrome.

Keywords: Prasugrel, Clopidogrel, Percutaneous coronary intervention, Bleeding events, Major adverse cardiac events

* Correspondence: huangfeng.7925@163.com

Institute of Cardiovascular Diseases and Guangxi Key Laboratory Base of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People’s Republic of China

Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The new anti-platelet agent prasugrel has been approved for use after percutaneous coronary intervention (PCI). Ending of the year 2017 has witnessed many research articles still focusing on anti-platelet agents following PCI [1, 2]. Due to limitations associated with clopidogrel, other newer oral anti-platelet agents which could potentially replace clopidogrel are presently still being studied.

Several recently published meta-analyses comparing prasugrel with clopidogrel are available in MEDLINE and other electronic databases. However, when those research were deeply assessed, several limitations were observed. To be clear, almost all of the meta-analyses compared clopidogrel versus a combination of prasugrel and ticagrelor [3]. For example, in 2013, a meta-analysis compared newer potential anti-platelet agents (prasugrel and ticagrelor combined together) with clopidogrel following PCI [4]. Similarly in 2015, another meta-analysis involving only 4 randomized controlled trials again compared newer oral P2Y12 inhibitors (prasugrel and ticagrelor) with clopidogrel [5].

Because data on this aspect were limited, indirect comparisons were also made through network meta-analyses [6]. Fortunately, one meta-analysis at least compared clopidogrel with prasugrel (without the inclusion of other newer oral P2Y12 inhibitors) [7]. However, a major shortcoming was the fact that a detailed comparison of bleeding events and other adverse cardiovascular outcomes were not carried out.

Therefore, in this analysis, we aimed to systematically carry out a detailed direct comparison of outcomes observed with prasugrel versus clopidogrel following PCI.

Methods
Searches databases and searched strategies
Common online searched databases (The Cochrane library, EMBASE, MEDLINE and Google scholar) were used to retrieve relevant publications.

Official websites of several cardiology journals were also carefully checked for relevant publications.

The following searched terms were used to retrieve English publications:
Prasugrel and clopidogrel; Oral P2Y12 inhibitors and clopidogrel; Prasugrel and percutaneous coronary intervention; Prasugrel and coronary angioplasty; Clopidogrel, prasugrel and percutaneous coronary intervention; Clopidogrel, prasugrel and PCI; Clopidogrel, prasugrel and acute coronary syndrome/ACS.

The above-mentioned searched databases were filtered for relevant publications, and those which were found important were at first saved in a specific folder to be further reviewed based on the inclusion and exclusion criteria.

Inclusion and exclusion criteria
Selection of relevant publications was based on the following inclusion criteria:

(a) Randomized controlled trials or observational studies;
(b) Comparing prasugrel versus clopidogrel following PCI; (c) Reporting adverse cardiovascular and bleeding outcomes among their clinical endpoints.

Publications were reviewed and then rejected based on the following exclusion criteria:

(a) They were non-English publications (it should be noted that non-English publications were excluded since the authors would not be able to fully understand the language and important information would be ignored or missed and inappropriate data would be included); (b) Case-control studies, review articles, or letter to editors; (c) The studies involved patients who were not undergoing PCI; (d) They compared prasugrel with clopidogrel, however, PCI was not involved; (e) They did not report adverse cardiovascular and bleeding outcomes; (f) They were duplicated studies; (g) They involved switching from clopidogrel to prasugrel or vice-versa (crossing over).

Types of participants, outcomes, definitions and follow-ups
Participants who underwent PCI were included in this analysis: patients with acute coronary syndrome (ACS) especially ST segment elevated myocardial infarction (STEMI) or patients who were candidates for elective PCI were included.

The primary endpoints were the adverse cardiovascular outcomes:
All-cause mortality; Cardiovascular death; Myocardial infarction (MI); Stroke; Stent thrombosis; Repeated revascularization; Major adverse cardiac events (including death, MI, revascularization/stroke).

The secondary endpoints were the bleeding outcomes:
‘All bleeding events’ was defined as any possible type of bleeding which was reported; Thrombolysis In Myocardial Infarction (TIMI) defined major bleeding [8]; TIMI defined minor bleeding [8].

The types of participants, the outcomes which were reported in each study as well as the follow-up periods were listed in Table 1.

Data extraction and quality assessment and statistical analysis
Two authors (PKB and FH) independently reviewed the searched databases and extracted data from relevant publications.

The following data were extracted from the studies:
Table 1 Reported outcomes, types of participants and follow ups

| Trials          | Outcomes                                      | Follow-up periods      | Types of participants             |
|-----------------|-----------------------------------------------|------------------------|-----------------------------------|
| INFUSE AMI [11] | All-cause death, MACEs, definite and probable ST, HORIZONS major bleeding | 30 days and 1 year     | STEMI undergoing PCI              |
| JUMBO TIMI 26   | Non-CABG TIMI major and minor bleeding, minimal bleeding, MACEs, all-cause death, stroke, MI, recurrent ischemia, ST | 30 days                | Elective or urgent PCI            |
| PRASFIT ACS [13]| MACEs, all-cause death, CV death, ST, revascularization, MI, stroke, TIMI defined minor and major bleeding | 6 months, 1 year       | ACS undergoing PCI                |
| PRINCIPLE TIMI 44 | TIMI major and minor bleeding, overall bleeding events, ST, MI, MACEs | 1 month                | Elective PCI                       |
| TAILOR [15]     | MACEs, MI, stroke, ST, CV death                | 1 month, 1.5 years     | Elective PCI                       |
| TRANSLATE ACS [16]| All-cause death, MI, stroke, revascularization, MACEs, BARC bleeding type 1–5, GUSTO moderate/severe bleeding | 6 months               | ACS undergoing PCI                |
| TRIGGER PCI [17]| MACEs, CV death, MI, definite and probable ST, all-cause death, TIMI major bleeding | 8 months               | Elective PCI                       |
| TRITON TIMI 38   | MACEs, CV death, all-cause death, MI, stroke, revascularization, ST, TIMI major or minor bleeding | 15 months              | STEMI undergoing PCI               |

Abbreviations: MACEs major adverse cardiac events, HORIZONS Harmonizing Outcomes with Revascularisation and Stents in Acute Myocardial Infarction, CABG coronary artery bypass grafting, TIMI thrombolysis in myocardial infarction, ST stent thrombosis, CV cardiovascular, MI myocardial infarction, GUSTO Global Use of Strategies to Open Occluded Arteries, BARC bleeding defined according to the academic research consortium, STEMI ST elevated myocardial infarction, PCI percutaneous coronary intervention, ACS acute coronary syndrome, CAD coronary artery disease, T2DM type 2 diabetes mellitus

Total number of participants who were treated by prasugrel and clopidogrel respectively; The baseline features and the types of participants; The loading and maintenance dosages of prasugrel and clopidogrel; The methodological qualities of the trials; The adverse cardiovascular and bleeding outcomes as well as the corresponding follow-up periods which were reported.

After data extraction, data were further cross-checked. Any disagreement was resolved by consensus.

The methodological quality of the trials were also assessed based on the criteria set by the Cochrane collaboration [9]. A grade ranging from A (lowest risk of bias) to E (highest risk of bias) was allotted to each trial based on the assessment.

This analysis was carried out by RevMan 5.3 (latest version), whereby odds ratios (OR) and 95% confidence intervals (CI) were considered as the statistical parameters.

Heterogeneity which is a common feature in meta-analyses, was assessed by:
(a) The Q statistic test whereby a $P$ value less or equal to 0.05 was considered as statistically significant; (b) The $I^2$ statistic test whereby heterogeneity increased with an increasing $I^2$ value.

A fixed ($I^2 < 50\%$) or a random ($I^2 > 50\%$) effects model was used based on the $I^2$ value which signified heterogeneity.

In addition, sensitivity analysis was carried out by a method of exclusion.

Publication bias was also assessed through funnel plots.

Results

Searched outcomes

The PRISMA guideline was followed [10]. This electronic search resulted in a total number of 2949 publications. After a careful assessment of the titles and the abstracts, 2794 irrelevant publications were eliminated.

Among the remaining 155 articles, further elimination was carried out (following a second review) based on the following criteria:

They were meta-analyses (7); They were review articles (4); They were case-control studies (3); They were letter to editors (3); They were not associated with PCI (2); They involved crossing over of drugs (switching from clopidogrel to prasugrel or vice versa) [8]; They reported platelet reactivity as outcomes (11); They were duplicated studies (109).

Finally, 8 trials [11–18] were included in this analysis as shown in Fig. 1.

General features of the studies

A total number of 18,122 participants were included in this direct analysis whereby 7051 participants were treated by prasugrel and 11,071 participants were treated by clopidogrel. The patients’ enrollment period varied from years 2003 and 2012. The general features of the studies were listed in Table 2.

Based on the assessment of the methodological quality of the trials, a grade was allotted to each of the trials as shown in Table 2.

All the patients received aspirin along with a loading dose of either prasugrel (60 mg in most of the cases) or clopidogrel (300 or 600 mg) prior to PCI. Following PCI, aspirin and either prasugrel (10 mg) or clopidogrel (75 mg or 150 mg) were continually used during the follow-up periods as shown in Table 3.
Baseline features of the studies
The baseline features of the participants have been listed in Table 4. The average age varied from 56 years to 65.8 years. Male participants were predominant in both groups. The percentage of participants with risk factors such as hypertension, diabetes mellitus, dyslipidemia, smoking history have been listed in Table 4. According to the baseline features, there was no significant difference between participants who were treated by prasugrel or clopidogrel following PCI.

Adverse cardiovascular outcomes observed with prasugrel versus clopidogrel following PCI
Results of this analysis showed prasugrel to be associated with significantly lower adverse cardiovascular outcomes in comparison to clopidogrel following PCI. All-cause mortality, MI, stroke, stent thrombosis and MACEs were significantly lower with prasugrel (OR: 0.47, 95% CI: 0.35–0.63; P = 0.0001), (OR: 0.68, 95% CI: 0.57–0.80; P = 0.00001), (OR: 0.60, 95% CI: 0.38–0.96; P = 0.03, OR: 0.46, 95% CI: 0.30–0.72; P = 0.0006) and (OR: 0.61, 95% CI: 0.53–0.70; P = 0.00001) respectively as shown in Fig. 2. Repeated revascularization was not significantly different (OR: 0.92, 95% CI: 0.80–1.06; P = 0.25) (Fig. 2).

When participants which were extracted only from randomized controlled trials were assessed, all-cause mortality favored prasugrel (OR: 0.70, 95% CI: 0.47–1.05; P = 0.09), with a P value approaching statistical significance. Prasugrel was still associated with lower MI (OR: 0.68, 95% CI: 0.57–0.80; P = 0.0001), stent thrombosis (OR: 0.49, 95% CI: 0.32–0.77; P = 0.002) and MACEs (OR: 0.74, 95% CI: 0.61–0.88; P = 0.0007).

The analysis which has been carried out above, included patients with STEMI undergoing PCI and other patients undergoing elective PCI.

When patients with ACS (mostly STEMI) were separately analyzed, all-cause mortality, MI, stroke, stent thrombosis and MACEs were still significantly lower with prasugrel as compared to clopidogrel (OR: 0.49, 95% CI: 0.28–0.85; P = 0.01), (OR: 0.68, 95% CI: 0.57–0.81; P = 0.0001), (OR: 0.55, 95% CI: 0.34–0.89; P = 0.01), (OR: 0.47, 95% CI: 0.29–0.78; P = 0.003) and (OR: 0.59, 95% CI: 0.42–0.82; P = 0.002) respectively as shown in Figs. 3 and 4.

Bleeding outcomes observed between prasugrel versus clopidogrel following PCI
When the bleeding outcomes were analyzed, TIMI defined major and minor bleeding were not significantly different (OR: 0.91, 95% CI: 0.66–1.27; P = 0.59) and (OR: 1.16, 95% CI: 0.85–1.59; P = 0.35) respectively as shown in Fig. 5.

However, ‘all bleeding events’ was significantly higher with prasugrel (OR: 1.32, 95% CI: 1.03–1.70; P = 0.03) as shown in Fig. 6.

| Trials                  | Type of study | Time period of patients’ enrollment (years) | No of patients treated by prasugrel (n) | No of patients treated by clopidogrel (n) | Total no of patients (n) | Bias risk grade |
|-------------------------|---------------|---------------------------------------------|-----------------------------------------|------------------------------------------|--------------------------|----------------|
| INFUSE AMI              | OS            | –                                           | 155                                     | 297                                      | 452                      | B              |
| JUMBO TIMI 26           | RCT           | 2003                                        | 650                                     | 254                                      | 904                      | A              |
| PRASFIT ACS             | RCT           | 2010–2012                                   | 685                                     | 678                                      | 1363                     | B              |
| PRINCIPLE TIMI 44       | RCT           | –                                           | 102                                     | 99                                       | 201                      | A              |
| TAILOR                  | RCT           | 2010–2012                                   | 54                                      | 52                                       | 106                      | B              |
| TRANSLATE ACS           | OS            | 2010–2012                                   | 3424                                    | 7715                                     | 11,139                   | A              |
| TRIGGER PCI             | RCT           | 2009–2011                                   | 212                                     | 211                                      | 423                      | A              |
| TRITON TIMI 38          | RCT           | 2004–2007                                   | 1769                                    | 1765                                     | 3534                     | A              |
| Total no of patients (n)|               |                                             | 7051                                    | 11,071                                   | 18,122                   |                |

Abbreviations RCT randomized controlled trials, OS observational study
When we included only participants which were obtained from randomized controlled trials, TIMI defined major (OR: 0.91, 95% CI: 0.66–1.27; \( P = 0.59 \)) and minor (OR: 1.16, 95% CI: 0.85–1.59; \( P = 0.35 \)) bleedings were still similarly manifested with prasugrel and clopidogrel.

In patients with STEMI, TIMI defined major bleeding, and TIMI defined minor bleeding were also not significantly different (OR: 0.90, 95% CI: 0.64–1.26; \( P = 0.53 \)) and (OR: 1.22, 95% CI: 0.62–2.39; \( P = 0.56 \)) respectively as shown in Figs. 3 and 4. Even if ‘all bleeding events’ was significantly higher in these patients with STEMI who underwent PCI, (OR: 1.31, 95% CI: 0.96–1.77; \( P = 0.09 \)), the result was not statistically significant as shown in Fig. 4.

In those patients without STEMI who underwent elective PCI, TIMI defined major, minor and ‘all bleeding events’ were not significantly different (OR: 1.21, 95% CI: 0.31–4.73; \( P = 0.79 \)), (OR: 3.62, 95% CI: 0.64–20.35; \( P = 0.14 \)) and (OR: 1.35, 95% CI: 0.80–2.28; \( P = 0.26 \)) respectively as shown in Fig. 7.

Sensitivity analysis was also carried out without any significantly different result compared to the main analysis. Consistent results were obtained throughout all the subgroups.

**Table 3** Loading and maintenance dosage of anti-platelet medications which were used by the participants

| Trials           | ASA administration throughout the study | GP IIb/IIIa LD of prasugrel | P/C | LD of clopidogrel | LD of prasugrel | MD of clopidogrel | MD of clopidogrel |
|------------------|----------------------------------------|-----------------------------|-----|-------------------|----------------|-------------------|-------------------|
| INFUSE AMI       | 100/100                                | +/-                         | –   | –                 | 10 mg          | 75 mg             |
| JUMBO TIMI 26    | 100/100                                | +/-                         | 60 mg| 300 mg            | 10 mg          | 75 mg             |
| PRASFIT ACS      | 100/100                                | 20 mg                       | 300 mg| 3.75 mg           | 75 mg          |
| PRINCIPLE TIMI 44| 100/100                                | –                           | 60 mg| 600 mg            | 10 mg          | 150 mg            |
| TAILOR           | 100/100                                | +/-                         | –   | 600 mg            | 10 mg          | 150 mg            |
| TRANSLATE ACS    | 100/100                                | –                           | –   | –                 | 10 mg          | 75 mg             |
| TRIGGER PCI      | 100/100                                | –                           | 60 mg| 600 mg            | 10 mg          | 75 mg             |
| TRITON TIMI 38   | 100/100                                | +/-                         | 60 mg| 300 mg            | 10 mg          | 75 mg             |

**Abbreviations:** P prasugrel, C clopidogrel, ASA aspirin, GP glycoprotein, LD loading dose, MD maintenance dose

**Publication bias**

This research analysis consisted of only eight studies. Funnel plots were most appropriate to represent publication bias for similar meta-analyses with a small number of studies. The funnel plot which was generated from Revman software showed low evidence of publication bias as shown in Fig. 8.

**Discussion**

Prasugrel is a new anti-platelet agent which might potentially replace clopidogrel following PCI [19, 20]. In this analysis, a direct detailed systematical comparison was carried out between prasugrel and clopidogrel following coronary angioplasty.

The current results showed prasugrel to be significantly better than clopidogrel in terms of efficacy whereby mortality, MACEs, stroke and stent thrombosis were significantly reduced following PCI. TIMI defined major and minor bleeding were similarly manifested with prasugrel and clopidogrel. However, the combination of other types of bleeding which was defined as ‘all bleeding events’ was significantly higher with prasugrel, but when STEMI patients and those patients who

**Table 4** Baseline features of the studies

| Trials            | Age (yrs) | Males (%) | HTN (%) | DSL (%) | DM (%) | CS (%) |
|-------------------|-----------|-----------|---------|---------|--------|--------|
| INFUSE AMI        | 57.6/62.7 | 79.4/71.0 | 24.5/35.0| 16.8/15.2| 9.7/12.1| 68.8/56.3|
| JUMBO TIMI 26     | 59.0/58.0 | 76.3/77.0 | –       | –       | 27.5/25.0| 23.3/31.0|
| PRASFIT ACS       | 65.4/65.1 | 78.2/79.4 | 72.3/72.4| 75.3/73.7| 36.5/35.0| 39.9/41.2|
| PRINCIPLE TIMI 44 | 64.0/63.8 | 71.6/77.8 | 85.3/77.8| 90.2/86.9| 32.4/29.3| 17.6/16.2|
| TAILOR            | 63.0/63.0 | 74.1/82.7 | 74.1/82.7| 83.3/88.5| 29.6/34.6| 77.8/67.3|
| TRANSLATE ACS     | 56.0/61.0 | 78.1/69.4 | 61.7/69.1| –       | 24.5/27.0| 40.4/38.6|
| TRIGGER PCI       | 65.8/66.3 | 72.2/73.0 | 88.7/89.1| –       | 41.0/42.7| 16.2/14.0|
| TRITON TIMI 38    | 58.0/59.0 | 79.0/76.0 | 49.0/50.0| 41.0/41.0| 19.0/19.0| 47.0/44.0|

**Abbreviations:** yrs. years, P prasugrel, C clopidogrel, HTN hypertension, DSL dyslipidemia, DM diabetes mellitus, CS current smoker
### Table 1

| Subgroup          | Prasugrel | Clopidogrel | Odds Ratio | M-H, Fixed, 95% CI |
|-------------------|-----------|-------------|------------|---------------------|
| **1.1 All-cause mortality** |           |             |            |                     |
| INFLAM AMI        | 2         | 155         | 25         | 1927                |
| JUMBO TIMI 26     | 3         | 650         | 0          | 254                 |
| PIASFIT ACS       | 11        | 685         | 11         | 678                 |
| TRANSATE ACS      | 21        | 3424        | 128        | 7715                |
| TRIGGER PCI       | 0         | 212         | 1          | 211                 |
| TRITON TIMI 38    | 28        | 1769        | 45         | 1765                |
| Subtotal (95% CI) | 6898      | 19929       | 9.6%       | 6.47 (3.56, 9.63)   |
| **Total events**  | 65        | 210         |            |                     |
| **Heterogeneity** | Chi2 = 9.37, df = 5 (P = 0.10); P = 0.47 |
| **Test for overall effect** | Z = 5.13 (P < 0.0001) |
| **1.2 Cardiovascular Death** |           |             |            |                     |
| PIASFIT ACS       | 10        | 685         | 8          | 678                 |
| TAILOR            | 2         | 54          | 6          | 52                 |
| TRIGGER PCI       | 0         | 212         | 1          | 211                 |
| TRITON TIMI 38    | 25        | 1769        | 41         | 1765                |
| Subtotal (95% CI) | 6720      | 2756        | 3.4%       | 0.68 (0.44, 1.03)   |
| **Total events**  | 37        | 54          |            |                     |
| **Heterogeneity** | Chi2 = 2.35, df = 2 (P = 0.31); I² = 15% |
| **Test for overall effect** | Z = 1.92 (P = 0.07) |
| **1.3 Myocardial Infarction** |           |             |            |                     |
| JUMBO TIMI 26     | 83        | 650         | 60         | 254                 |
| PIASFIT ACS       | 58        | 685         | 68         | 678                 |
| TRANSATE ACS      | 10        | 3424        | 228        | 7715                |
| TRIGGER PCI       | 12        | 212         | 1          | 211                 |
| TRITON TIMI 38    | 25        | 1769        | 123        | 1765                |
| Subtotal (95% CI) | 5878      | 19928       | 24.1%      | 0.92 (0.80, 1.06)   |
| **Total events**  | 242       | 437         |            |                     |
| **Heterogeneity** | Chi2 = 2.21, df = 4 (P = 0.70); I² = 0% |
| **Test for overall effect** | Z = 4.66 (P < 0.0001) |
| **1.4 Revascularization** |           |             |            |                     |
| PIASFIT ACS       | 107       | 685         | 96         | 678                 |
| TRANSATE ACS      | 190       | 3424        | 478        | 7715                |
| TRITON TIMI 38    | 22        | 1769        | 33         | 1765                |
| Subtotal (95% CI) | 5678      | 19924       | 24.1%      | 0.92 (0.80, 1.06)   |
| **Total events**  | 319       | 627         |            |                     |
| **Heterogeneity** | Chi2 = 3.27, df = 3 (P = 0.39); I² = 39% |
| **Test for overall effect** | Z = 4.66 (P < 0.0001) |
| **1.5 Stroke** |           |             |            |                     |
| JUMBO TIMI 26     | 2         | 650         | 0          | 254                 |
| PIASFIT ACS       | 6         | 685         | 10         | 678                 |
| TAILOR            | 1         | 54          | 0          | 52                 |
| TRANSATE ACS      | 10        | 3424        | 37         | 7715                |
| TRITON TIMI 38    | 7         | 1769        | 16         | 1765                |
| Subtotal (95% CI) | 6982      | 19928       | 24.1%      | 0.92 (0.80, 1.06)   |
| **Total events**  | 27        | 53          |            |                     |
| **Heterogeneity** | Chi2 = 2.46, df = 4 (P = 0.65); I² = 0% |
| **Test for overall effect** | Z = 2.92 (P = 0.003) |
| **1.6 Bleeding events** |           |             |            |                     |
| INFLAM AMI        | 0         | 155         | 7          | 297                 |
| JUMBO TIMI 26     | 4         | 650         | 6          | 254                 |
| PIASFIT ACS       | 4         | 685         | 5          | 678                 |
| PRINCIPLE TIMI 44 | 0         | 102         | 1          | 99                  |
| TAILOR            | 3         | 54          | 3          | 52                 |
| TRIGGER PCI       | 0         | 212         | 0          | 211                 |
| TRITON TIMI 38    | 19        | 1769        | 39         | 1765                |
| Subtotal (95% CI) | 3627      | 33356       | 3.9%       | 0.40 (0.30, 0.52)   |
| **Total events**  | 30        | 61          |            |                     |
| **Heterogeneity** | Chi2 = 3.09, df = 5 (P = 0.69); I² = 0% |
| **Test for overall effect** | Z = 5.43 (P < 0.0001) |
| **1.7 Major adverse cardiac events (MACEs)** |           |             |            |                     |
| INFLAM AMI        | 5         | 155         | 42         | 297                 |
| JUMBO TIMI 26     | 47        | 650         | 24         | 254                 |
| PIASFIT ACS       | 74        | 685         | 84         | 678                 |
| PRINCIPLE TIMI 44 | 2         | 102         | 1          | 99                  |
| TAILOR            | 5         | 54          | 7          | 52                 |
| TRANSATE ACS      | 91        | 3424        | 390        | 7715                |
| TRIGGER PCI       | 2         | 212         | 2          | 211                 |
| TRITON TIMI 38    | 115       | 1769        | 166        | 1765                |
| Subtotal (95% CI) | 7051      | 11071       | 33.6%      | 0.81 (0.63, 0.97)   |
| **Total events**  | 341       | 716         |            |                     |
| **Heterogeneity** | Chi2 = 13.65, df = 7 (P = 0.06); P = 0.49 |
| **Test for overall effect** | Z = 6.92 (P < 0.0001) |

**Fig. 2** Adverse cardiovascular outcomes observed with prasugrel versus clopidogrel following PCI
underwent elective PCI were separately analyzed, no significant bleeding event was reported between prasugrel and clopidogrel.

This analysis showed robust results in comparison to another recently published meta-analysis [7]. Even though the current results were supported by the previous analysis (by Chen et al.), the latter involved several possible limitations. First of all, even though their analysis was based on patients post PCI, trials which did not involve patients who were revascularized by PCI were also included, contributing to its high total number of patients [21, 22]. In addition, trials which involved switching from clopidogrel to prasugrel or vice versa were also included [22]. Also, detailed outcomes were not assessed and the results which were reported showed an extremely high level of heterogeneity (up to 93%) in several subgroups [7]. The main strength of this current analysis was that it successfully resolved those flaws and limitations to provide a new analysis with robust results, with low heterogeneity in several of the subgroups, and reported a detailed analysis of the cardiovascular and bleeding outcomes.

Another analysis which was published on this aspect, involved a combination of prasugrel and ticagrelor which we think would be unfair to represent a result specifically based on prasugrel since it was associated with a combination of two anti-platelet agents [5].

In a Veterans Affairs population, prasugrel was proven to be significantly better compared to clopidogrel post PCI in terms of adverse cardiovascular events supporting the results of this analysis. Bleeding events were also not significantly higher [23].

In addition, a TRial to assess Improvement in Thera-apeutic Outcomes by optimizing platelet inhibitoN with...
prasugrel (TRITON)–Thrombolysis in Myocardial Infarction (TIMI) 38 Sub-study also showed results which supported this current analysis whereby prasugrel reduced ischemic events in comparison to clopidogrel [24].

Other studies have shown prasugrel to be even better than doubling the dosage of clopidogrel following stenting [25].

Furthermore, a retrospective study which compared prasugrel with clopidogrel in patients with ACS following coronary stenting also supported the current results showing significantly lower MI 1 year post PCI. The rate of minimal hemorrhage was higher with prasugrel but however, mortality was similar with both anti-platelet agents [26].
Another retrospective study showed prasugrel and clopidogrel to be similar in terms of adverse outcomes and bleeding events and the authors concluded that prasugrel was equally effective and safe [27]. This result was different from ours in terms of efficacy. But, the retrospective study was based on one single center whereas our current analysis involving mainly randomized patients from several larger trials, is believed to represent a better result.

However, the management of ACS does not only depend on anti-platelet agents. We should also emphasize on recent guidelines about how to manage patients with STEMI and NSTEMI. In this current analysis, more than 90% of the patients had STEMI whereas the remaining were NSTEMI patients. The 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation myocardial infarction gives a detailed explanation and treatment strategies of patients with STEMI [28] whereas the 2012 ACCF/AHA focused on the update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina and non-STEMI [29].

It should also be noted that diabetes mellitus and the associated medications might further influence the results of this analysis. In this analysis, each study included an average of 9.70 to 42.7% of patients with type 2 diabetes mellitus. However, a separate analysis of prasugrel versus clopidogrel in patients with diabetes mellitus was not possible because the trials did not report clinical outcomes and events separately for this particular subgroup of patients.

At last, it should be noted that incretin, a newer hypoglycemic drug, might also affect the prognosis of patients with diabetes mellitus and coronary artery
disease. The effects of incretin treatment on cardiovascular outcomes in diabetic patients with STEMI [30] and NSTEMI [31] have previously been studied. However, in this current analysis, we were unable to assess the percentage of STEMI and NSTEMI patients on incretin treatment.

Limitations

Even if the total number of patients were sufficient to reach a fair conclusion, several different subgroups reported less patients because the adverse cardiovascular outcomes and bleeding events were not reported in all of the trials; Different trials had different follow-up periods (1 month, 1 year to 5 years), and the follow-up periods were not taken into consideration; In addition, studies with planned PCI and ACS were mixed and analyzed at first; The other anti-platelet agents such as glycoprotein IIb/IIIa and double dose clopidogrel (150 mg instead of 75 mg), as well as the loading dose of prasugrel and clopidogrel which were different in certain studies might have influenced the results which were obtained; Moreover, publication bias was represented by funnel plots which were generated through the RevMan software. Any other additional statistical test was not carried out because the volume of studies was not sufficient.

Conclusions

Adverse cardiovascular outcomes were significantly lower with the use of prasugrel in comparison to clopidogrel following PCI. In addition, TIMI defined major and minor bleeding were not significantly different showing prasugrel to be well-tolerated following PCI especially in patients with ACS. Future studies should be based on patients with diabetes mellitus.

Abbreviations

ACS: Acute coronary syndrome; MACEs: Major adverse cardiac events; PCI: Percutaneous coronary intervention; TIMI: Thrombolysis in myocardial infarction

Funding

This research was supported by National Natural Science Foundation of China (No. 81560046), Guangxi Natural Science Foundation (No. 2016GXNSFAA380002), Scientific Project of Guangxi Higher Education (No. KY2015ZD028), Science Research and Technology Development Project of Qingxiu District of Nanning (No. 2016058) and Lisheng Health Foundation pilotage fund of Peking (No. LHJJ20158126).

Availability of data and materials

All data and materials used in this research are freely available in electronic databases (MEDLINE, EMBASE, Cochrane database, Google scholar). References have been provided.

Authors’ contributions

PKB and FH were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. PKB wrote the final manuscript. Both authors read and approved the final manuscript.

Authors’ information

Dr. Pravesh Kumar Bundhun (M.D) is the first author. From the Department of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Ethics approval and consent to participate

Ethical approval was not applicable for this systematic review and meta-analysis.

Competing interests

The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People's Republic of China.
2Institute of Cardiovascular Diseases and Guangxi Key Laboratory Base of Precision Medicine in Cardio-cerebrovascular Diseases Control and Prevention, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, People’s Republic of China.

Received: 16 February 2018 Accepted: 26 April 2018
Published online: 02 May 2018

References
1. Rodriguez AE, Rodriguez-Granillo AM, Ascarrunz SD, Peralta-Bazan F, Cho MY. Did Prasugrel and Ticagrelor offer the same benefit in patients with acute coronary syndromes after percutaneous coronary interventions compared to Clopidogrel? Insights from randomized clinical trials, registries and meta-analysis. Curr Pharm Des. 2018; https://doi.org/10.2174/138161282466180108121834.
2. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Impact of clopidogrel and potent P2Y12 inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Thromb Haemost. 2013;109(1):93–101.
3. Bavishi C, Panwar S, Messerei FH, Bangalore S. Meta-analysis of comparison of the newer oral P2Y12 inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol. 2015;116(8):A89–17.
4. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelethal prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.
5. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelethal prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.
6. Chatterjee S, Ghose A, Sharma A, Guha G, Mukherjee D, Frankel R. Comparing newer oral anti-platelethal prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. J Thromb Thrombolysis. 2013;36(3):223–32.
(150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv. 2011;4(4):403–10.

26. Lalor N, Rodríguez L, Elissamburu P, Filipini E, Conde D, Nau G, Cura F, Trivi M. Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty. Medicina (B Aires). 2015;75(4):207–12.

27. Wang A, Lella LK, Brener SJ. Efficacy and safety of Prasugrel compared with Clopidogrel for patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Ther. 2016;23(6):e1637–43.

28. Ibanez B, James S, Ageballi S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenza MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.

29. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chaey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Jneid H, Ettinger SM, Ganiats TG, Philippon J, Jacobs AK, Halperin JL, Albert NM, Creager MA, DeMets D, Guyton RA, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;61(23):e179–347.

30. Marfella R, Sardu C, Balestrieri ML, Siniscalchi M, Minicucci F, Signoriello G, Calabro P, Mauro C, Pierotti G, Coppola A, Nicoletti G, Rizzo MR, Paolisso G, Barbieri M. Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit-occlusive and multivessel non-obstructive coronary artery stenosis. Diabetol Metab Syndr. 2018;10:1.

31. Marfella R, Sardu C, Calabro P, Siniscalchi M, Minicucci F, Signoriello G, Balestrieri ML, Mauro C, Rizzo MR, Paolisso G, Barbieri M. Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: effects of incretin treatment. Diabetes Obes Metab. 2018;20(3):723–9.